Seeking Alpha

PharMerica upgraded

  • Credit Suisse upgrades PharMerica (PMC) to Outperform and raises its price target from $19 to $30.
  • Analyst Glen Santangelo cites the company's accelerating growth profile as the main reason for his bullish outlook.
  • Consensus estimates for 2014 and 2015 are $1.47/share on revenues of $1.68B and $1.75/share on revenues of $1.72B, respectively.
  • 282 mutual funds have positions.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector